Journal
JOURNAL OF MOLECULAR MEDICINE-JMM
Volume 99, Issue 7, Pages 917-931Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00109-021-02071-5
Keywords
Nrf2; Parkinson’ s disease; Oxidative stress; Keap1; Antioxidants
Funding
- National Natural Science Foundation of China [81873133, 81373629, 81241107, 81073080, 81673686, 81473407, 81273640, 81141117, 30973925, 30873396]
Ask authors/readers for more resources
Parkinson's disease is a complex neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the brain. Current treatments focus on symptom relief rather than modifying the course of the disease. Oxidative stress, caused by genetic and environmental factors, is thought to play a key role in the development of Parkinson's disease. Targeting Nrf2, a key regulator of redox homeostasis, may offer a therapeutic option to alleviate oxidative stress in Parkinson's disease.
Parkinson's disease (PD) is a complex neurodegenerative disorder featuring both motor and nonmotor symptoms associated with a progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Conventionally, PD treatment options have focused on dopamine replacement and provide only symptomatic relief. However, disease-modifying therapies are still unavailable. Mechanistically, genetic and environmental factors can produce oxidative stress which has been implicated as a core contributor to the initiation and progression of PD through the degeneration of dopaminergic neurons. Importantly, nuclear factor erythroid 2-related factor 2 (Nrf2) is essential for maintaining redox homeostasis by binding to the antioxidant response element which exists in the promoter regions of most genes coding for antioxidant enzymes. Furthermore, protein kinase C, mitogen-activated protein kinases, and phosphotidylinositol 3-kinase have been implicated in the regulation of Nrf2 activity during PD. Here, we review the evidence supporting the regulation of Nrf2 through Keap1-dependent and Keap1-independent mechanisms. We also address that targeting Nrf2 may provide a therapeutic option to mitigate oxidative stress-associated PD. Finally, we discuss currently known classes of small molecule activators of Nrf2, including Nrf2-activating compounds in PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available